Portal de Periódicos da CAPES

RSV Immune Globulin Prophylaxis: Is an Ounce of Prevention Worth a Pound of Cure?

1999; American Academy of Pediatrics; Volume: 104; Issue: 3 Linguagem: Inglês

10.1542/peds.104.3.559

1098-4275

Frank W. Moler,

Pneumonia and Respiratory Infections

In this issue of Pediatrics,Joffe et al reported limited cost-effectiveness of the immune globulin products (RSV-IGIV [Respigam] or palivizumab [Synagis]) to prevent RSV hospitalization. Several assumptions strongly favoring immune globulin prophylaxis were used in their analyses. The authors concluded that current AAP recommendations regarding RSV immune globulin products may be too broad because a lack of cost-effectiveness observed.1 In only 1 of the 8 subgroup analyses (Group A infants with gestation 40%) and costs per year of life saved increased from $33 000 to $48 110 (>45%). Additionally, it was assumed that no drug wastage occurs; a condition unlikely to be met in actual practice. Finally, efficacy from randomized clinical trial reports was used as a measure of effectiveness in actual clinical practice. When products are used outside clinical trials, effectiveness may be reduced because ideal study conditions no longer exist (timely dosing, education concerning avoidance of exposure to high-risk settings, etc). Despite these major assumptions favorable to active prophylaxis, the authors conclude immune globulin products do not appear cost-effective for most subgroups.The authors make one major assumption related to cost-effectiveness of RSV immune globulin therapies, upon which other major findings of their report depend and which may not be justified. This assumption is that mortality of RSV correlates directly with hospital admission rate rather than treatment status. Because immune globulin prophylaxis reduces hospitalization by about 50%, this would result in a major increase in the mortality risk for the no prophylaxis control group at a ratio of about 2:1 compared with the actively treated group. This critical assumption is not supported in the literature but has been made before.2 In the three randomized clinical trials from which the authors derived the 1.2% pooled mortality estimate for RSV hospitalization,3–5 there were 2 deaths in 173 hospitalized RSV patients described. However, both hospital deaths occurred in patients receiving previous prophylaxis rather than control patients. Concern of increased morbidity or trends for increased mortality associated with immune globulin prophylaxis has been observed in patients with congenital heart disease and has resulted in recommendations against immune globulin prophylaxis in select patients.1,3,6 (Had the authors assumed that death occurred only in patients receiving immune globulin, the analysis would be highly against immune globulin administration because of increased mortality and increased cost). The authors artificially created a twofold increase in mortality in the no treatment group, which has no valid basis. Without this assumption, there exists no life-years saved and no cost per life-year saved to be reported for either of the RSV immune globulin products.In this reviewer's opinion, expert committees responsible for recommendations related to expensive therapeutic agents will need to become more proactive in the future and not bypass cost-effectiveness issues when publishing practice guidelines.1 Because of limited health care resources, expert committees must make their best estimate of cost-effectiveness when ideal data are not available. The time lag until well-designed generalizable postmarketing studies are published may be several years. In the meantime, costs will be simply set by those most likely to benefit (eg, a pharmaceutical company). It may be to a company's advantage under some circumstances not to sponsor well-conceived generalizable phase IV postmarketing cost-effectiveness studies. Unfortunately, the Food and Drug Administration does not assess agents for cost-effectiveness before approval and the long, rigorous funding process through agencies such as the National Institutes of Health or the Agency for Health Care Policy Research would result in long delays to eventual study publication.At this time, there is no evidence that RSV immune globulin products improve RSV mortality resulting in years of life saved at any cost. Other reports7–9 also suggest that immune globulin products to prevent RSV hospitalization are too highly priced, based on currently available information regarding benefits actually observed. Further research is needed to define patient groups likely to have acceptable cost-effectiveness resulting from RSV immune globulin administration. Research into potentially less expensive educational methods to prevent RSV infection should also be performed. Expert committees may need to update existing immune globulin recommendations. A recommendation for major cost reduction in these products and additional phase IV postmarketing effectiveness research seems appropriate. In the case of RSV immune globulin products, “an ounce of prevention” does not result “in a pound of cure” based on currently available information.